Q-omics provides the consensus-scored FBXL8 profile across patient tissues and cancer cell-line models. FBXL8 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FBXL8 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, FBXL8 protein abundance shows 28,113 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRC, and LSCC as cancer lineages where FBXL8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXL8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXL8 survival associations across molecular data types. FBXL8 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXL8 RNA expression–survival associations across cancer types. High FBXL8 expression shows unfavorable associations in ACC, LGG and LUSC, but favorable associations in MESO, UCEC and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for FBXL8 RNA expression.
This table summarizes FBXL8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FBXL8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXL8 shows higher tumor expression in KIRC, BLCA, COAD, KIRP, LIHC and STAD. The KIRC box plot shows higher FBXL8 RNA expression in tumor versus normal tissue (log2 FC = +1.280, t-test p < 0.001).
This table shows molecular features associated with FBXL8 in patient tissues and cancer cell lines. In patient samples, FBXL8 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXL8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
